I am writing today to share some exciting personal and professional changes.

After a brief leave, I will return to the Foundation as the Foundation’s first-ever Director of Research.  I am honored to be moving into this important position focusing exclusively on advancing the foundation’s research portfolio and advancing the progress we have achieved together.

As I reflect on the last five years as Executive Director, I am incredibly proud of all that the foundation has achieved.  Last year brought some of the biggest breakthroughs in neuroendocrine tumor research-to-date, and I look forward to working with you to build on these groundbreaking results.

I am incredibly excited about the addition of Ron Hollander to the team as CFCF’s new Executive Director. Ron is an experienced health care executive whose strategic skills and collaborative leadership helped propel the Massachusetts Hospital Association to national prominence during his more than decade-long tenure as its President and CEO. 

The Foundation’s success is a result of the hard work of staff as well as the unwavering commitment and dedication of our Board of Directors, Board of Scientific Advisors and most importantly, you, our supporters.  Thank you for the opportunity to work with you to advance neuroendocrine tumor understanding to bring about cures and effective treatments for patients.

All my best,